<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Abivax Sa — News on 6ix</title>
    <link>https://6ix.com/company/abivax-sa</link>
    <description>Latest news and press releases for Abivax Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 20 Apr 2026 20:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/abivax-sa" rel="self" type="application/rss+xml" />
    <item>
      <title>Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-annual-ordinary-and-extraordinary-general-meeting-of-may-11-2026-availability-of-the-preparatory-documents</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-annual-ordinary-and-extraordinary-general-meeting-of-may-11-2026-availability-of-the-preparatory-documents</guid>
      <pubDate>Mon, 20 Apr 2026 20:05:00 GMT</pubDate>
      <description>Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026Availability of the Preparatory Documents PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris &amp; Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders that its ordinary and extraordinar</description>
    </item>
    <item>
      <title>Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-publishes-financial-reports-with-the-french-and-us-securities-regulatory-agencies</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-publishes-financial-reports-with-the-french-and-us-securities-regulatory-agencies</guid>
      <pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
      <description>Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S.</description>
    </item>
    <item>
      <title>Abivax Announces Full Year 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-announces-full-year-2025-financial-results-and-provides-business-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-announces-full-year-2025-financial-results-and-provides-business-updates</guid>
      <pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
      <description>Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026</description>
    </item>
    <item>
      <title>Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-presents-first-evidence-of-anti-fibrotic-activity-for-obefazimod-alongside-new-clinical-efficacy-and-safety-analyses-in-inflammatory-bowel-disease-at-ecco-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-presents-first-evidence-of-anti-fibrotic-activity-for-obefazimod-alongside-new-clinical-efficacy-and-safety-analyses-in-inflammatory-bowel-disease-at-ecco-2026</guid>
      <pubDate>Sat, 21 Feb 2026 11:00:00 GMT</pubDate>
      <description>Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel diseaseAnti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, sugg</description>
    </item>
    <item>
      <title>Abivax Provides 2026 Corporate Outlook</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-provides-2026-corporate-outlook-210500457</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-provides-2026-corporate-outlook-210500457</guid>
      <pubDate>Wed, 07 Jan 2026 21:05:00 GMT</pubDate>
      <description>Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD spaceABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found no new safety signals with over 80% of participants having completed the 44-week double blind maintenance trialABTECT-UC Phase 3 maintenance topline results expected late Q2 2026, with a subsequen</description>
    </item>
    <item>
      <title>Abivax to be Added to Nasdaq Biotechnology Index</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-be-added-nasdaq-biotechnology-index-2025-12-18</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-be-added-nasdaq-biotechnology-index-2025-12-18</guid>
      <pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
      <description>Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq:</description>
    </item>
    <item>
      <title>Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-announces-acceptance-22-abstracts-evaluating-obefazimod-inflammatory-bowel</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-announces-acceptance-22-abstracts-evaluating-obefazimod-inflammatory-bowel</guid>
      <pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
      <description>Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical</description>
    </item>
    <item>
      <title>Abivax Presents Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-presents-third-quarter-2025-financial-results-2025-12-15</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-presents-third-quarter-2025-financial-results-2025-12-15</guid>
      <pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
      <description>Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS,</description>
    </item>
    <item>
      <title>Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-announces-patient-reported-outcomes-data-phase-3-abtect-induction-trials</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-announces-patient-reported-outcomes-data-phase-3-abtect-induction-trials</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of</description>
    </item>
    <item>
      <title>Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-announces-late-breaking-presentation-8-week-abtect-induction-trial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-announces-late-breaking-presentation-8-week-abtect-induction-trial-results</guid>
      <pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
      <description>Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced</description>
    </item>
    <item>
      <title>Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-announces-late-breaking-presentation-8-week-abtect-trial-results-updated</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-announces-late-breaking-presentation-8-week-abtect-trial-results-updated</guid>
      <pubDate>Sun, 05 Oct 2025 04:00:00 GMT</pubDate>
      <description>Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4%</description>
    </item>
    <item>
      <title>Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-announces-acceptance-additional-late-breaking-abstract-abtect-phase-3</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-announces-acceptance-additional-late-breaking-abstract-abtect-phase-3</guid>
      <pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
      <description>Abivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European</description>
    </item>
    <item>
      <title>Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-announces-presentation-late-breaking-abstract-obefazimod-abtect-phase-3</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-announces-presentation-late-breaking-abstract-obefazimod-abtect-phase-3</guid>
      <pubDate>Tue, 23 Sep 2025 04:00:00 GMT</pubDate>
      <description>Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG)</description>
    </item>
    <item>
      <title>Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-join-cac-mid-60-and-sbf-120-indices-following-euronext-paris-annual-review</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-join-cac-mid-60-and-sbf-120-indices-following-euronext-paris-annual-review</guid>
      <pubDate>Fri, 12 Sep 2025 04:00:00 GMT</pubDate>
      <description>Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext</description>
    </item>
    <item>
      <title>Abivax Presents First Half 2025 Financial Results</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-presents-first-half-2025-financial-results-2025-09-08</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-presents-first-half-2025-financial-results-2025-09-08</guid>
      <pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
      <description>Abivax Presents First Half 2025 Financial Results PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq</description>
    </item>
    <item>
      <title>Abivax Announces Closing of $747.5 Million Public Offering</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-announces-closing-7475-million-public-offering-2025-07-28</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-announces-closing-7475-million-public-offering-2025-07-28</guid>
      <pubDate>Mon, 28 Jul 2025 04:00:00 GMT</pubDate>
      <description>Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX)</description>
    </item>
    <item>
      <title>Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-announces-full-exercise-underwriters-option-purchase-additional-adss-bringing</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-announces-full-exercise-underwriters-option-purchase-additional-adss-bringing</guid>
      <pubDate>Fri, 25 Jul 2025 04:00:00 GMT</pubDate>
      <description>Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) PARIS, France,</description>
    </item>
    <item>
      <title>Abivax announces trading resumption of its ordinary shares on Euronext Paris</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-announces-trading-resumption-its-ordinary-shares-euronext-paris-2025-07-24</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-announces-trading-resumption-its-ordinary-shares-euronext-paris-2025-07-24</guid>
      <pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
      <description>Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris:</description>
    </item>
    <item>
      <title>Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-announces-pricing-650m-eu554m-public-offering-american-depositary-shares-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-announces-pricing-650m-eu554m-public-offering-american-depositary-shares-2025</guid>
      <pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
      <description>Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext</description>
    </item>
    <item>
      <title>Abivax announces temporary trading halt of its ordinary shares on Euronext Paris</title>
      <link>https://6ix.com/company/abivax-sa/news/abivax-announces-temporary-trading-halt-its-ordinary-shares-euronext-paris-2025-07-24</link>
      <guid isPermaLink="true">https://6ix.com/company/abivax-sa/news/abivax-announces-temporary-trading-halt-its-ordinary-shares-euronext-paris-2025-07-24</guid>
      <pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
      <description>Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris:</description>
    </item>
  </channel>
</rss>